↓ Skip to main content

Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML

Overview of attention for article published in Clinical Lymphoma, Myeloma & Leukemia, June 2013
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (72nd percentile)
  • Above-average Attention Score compared to outputs of the same age and source (57th percentile)

Mentioned by

patent
3 patents

Readers on

mendeley
90 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML
Published in
Clinical Lymphoma, Myeloma & Leukemia, June 2013
DOI 10.1016/j.clml.2013.03.019
Pubmed ID
Authors

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 90 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 90 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Researcher 12 13%
Student > Ph. D. Student 10 11%
Student > Master 9 10%
Student > Bachelor 8 9%
Other 7 8%
Other 20 22%
Unknown 24 27%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 24 27%
Biochemistry, Genetics and Molecular Biology 15 17%
Agricultural and Biological Sciences 9 10%
Nursing and Health Professions 8 9%
Pharmacology, Toxicology and Pharmaceutical Science 5 6%
Other 5 6%
Unknown 24 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 October 2019.
All research outputs
#7,591,076
of 34,410,798 outputs
Outputs from Clinical Lymphoma, Myeloma & Leukemia
#548
of 2,688 outputs
Outputs of similar age
#55,962
of 245,103 outputs
Outputs of similar age from Clinical Lymphoma, Myeloma & Leukemia
#6
of 19 outputs
Altmetric has tracked 34,410,798 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 2,688 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.1. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 245,103 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.